UNLABELLED: What's known on the subject? and What does the study add? Over-treatment of indolent prostate cancer lesions is a problem which can result in increased human and medical costs. Lesions with a low suspician level at mpMRI of the prostate have low risk of including high risk prostate cancer. OBJECTIVE: To determine whether multiparametric magnetic resonance imaging (mpMRI) has the potential to identify patients at low risk for cancer, thus obviating the need for biopsy. Prostate cancer is currently diagnosed by random biopsies, resulting in the discovery of multiple low-risk cancers that often lead to overtreatment. PATIENTS AND METHODS: We reviewed 800 consecutive patients who underwent a 3 Tesla mpMRI of the prostate with an endorectal coil from March 2007 to November 2011. All suspicious lesions were independently reviewed by two radiologists using T2-weighted, diffusion-weighted, spectroscopic and dynamic contrast-enhanced MRI sequences. Patients with only low suspicion lesions (maximum of two positive parameters on mpMRI) who subsequently underwent transrectal ultrasonography (TRUS)/MRI fusion targeted biopsy were selected for analysis. RESULTS: In total, 125 patients with only low suspicion prostatic lesions on mpMRI were identified. On TRUS/MRI fusion biopsy, 77 (62%) of these patients had no cancer detected, 38 patients had Gleason 6 disease and 10 patients had Gleason 7 (3+4) disease. There were 30 patients with cancer detected on biopsy who qualified for active surveillance using 2011 National Comprehensive Cancer Network guidelines. No cases of high-risk (≥ Gleason 4+3) cancer were identified on biopsy and, of the fifteen patients who underwent radical prostatectomy at our institution, none were pathologically upgraded to high-risk cancer. Thus, for patients with only low suspicion lesions, 107 (88%) patients either had no cancer or clinically insignificant disease. CONCLUSIONS: The results obtained in the present study show that low suspicion lesions on mpMRI are associated with either negative biopsies or low-grade tumours suitable for active surveillance. Such patients have a low risk of harbouring high-risk prostate cancers.
UNLABELLED: What's known on the subject? and What does the study add? Over-treatment of indolent prostate cancer lesions is a problem which can result in increased human and medical costs. Lesions with a low suspician level at mpMRI of the prostate have low risk of including high risk prostate cancer. OBJECTIVE: To determine whether multiparametric magnetic resonance imaging (mpMRI) has the potential to identify patients at low risk for cancer, thus obviating the need for biopsy. Prostate cancer is currently diagnosed by random biopsies, resulting in the discovery of multiple low-risk cancers that often lead to overtreatment. PATIENTS AND METHODS: We reviewed 800 consecutive patients who underwent a 3 Tesla mpMRI of the prostate with an endorectal coil from March 2007 to November 2011. All suspicious lesions were independently reviewed by two radiologists using T2-weighted, diffusion-weighted, spectroscopic and dynamic contrast-enhanced MRI sequences. Patients with only low suspicion lesions (maximum of two positive parameters on mpMRI) who subsequently underwent transrectal ultrasonography (TRUS)/MRI fusion targeted biopsy were selected for analysis. RESULTS: In total, 125 patients with only low suspicion prostatic lesions on mpMRI were identified. On TRUS/MRI fusion biopsy, 77 (62%) of these patients had no cancer detected, 38 patients had Gleason 6 disease and 10 patients had Gleason 7 (3+4) disease. There were 30 patients with cancer detected on biopsy who qualified for active surveillance using 2011 National Comprehensive Cancer Network guidelines. No cases of high-risk (≥ Gleason 4+3) cancer were identified on biopsy and, of the fifteen patients who underwent radical prostatectomy at our institution, none were pathologically upgraded to high-risk cancer. Thus, for patients with only low suspicion lesions, 107 (88%) patients either had no cancer or clinically insignificant disease. CONCLUSIONS: The results obtained in the present study show that low suspicion lesions on mpMRI are associated with either negative biopsies or low-grade tumours suitable for active surveillance. Such patients have a low risk of harbouring high-risk prostate cancers.
Authors: Ardeshir R Rastinehad; Angelo A Baccala; Paul H Chung; Juan M Proano; Jochen Kruecker; Sheng Xu; Julia K Locklin; Baris Turkbey; Joanna Shih; Gennady Bratslavsky; W Marston Linehan; Neil D Glossop; Pingkun Yan; Samuel Kadoury; Peter L Choyke; Bradford J Wood; Peter A Pinto Journal: J Urol Date: 2011-01-15 Impact factor: 7.450
Authors: Baris Turkbey; Vijay P Shah; Yuxi Pang; Marcelino Bernardo; Sheng Xu; Jochen Kruecker; Julia Locklin; Angelo A Baccala; Ardeshir R Rastinehad; Maria J Merino; Joanna H Shih; Bradford J Wood; Peter A Pinto; Peter L Choyke Journal: Radiology Date: 2010-12-21 Impact factor: 11.105
Authors: Wesley W Choi; Stephen B Williams; Xiangmei Gu; Stuart R Lipsitz; Paul L Nguyen; Jim C Hu Journal: J Urol Date: 2011-03-17 Impact factor: 7.450
Authors: Matthew R Cooperberg; Janet E Cowan; Joan F Hilton; Adam C Reese; Harras B Zaid; Sima P Porten; Katsuto Shinohara; Maxwell V Meng; Kirsten L Greene; Peter R Carroll Journal: J Clin Oncol Date: 2010-11-29 Impact factor: 44.544
Authors: Peter A Pinto; Paul H Chung; Ardeshir R Rastinehad; Angelo A Baccala; Jochen Kruecker; Compton J Benjamin; Sheng Xu; Pingkun Yan; Samuel Kadoury; Celene Chua; Julia K Locklin; Baris Turkbey; Joanna H Shih; Stacey P Gates; Carey Buckner; Gennady Bratslavsky; W Marston Linehan; Neil D Glossop; Peter L Choyke; Bradford J Wood Journal: J Urol Date: 2011-08-17 Impact factor: 7.450
Authors: Debra J Jacobson; Jennifer L St Sauver; Alexander S Parker; Michaela E McGree; Aruna V Sarma; Cynthia J Girman; Michael M Lieber; Steven J Jacobsen Journal: Urology Date: 2010-08-30 Impact factor: 2.649
Authors: Sheng Xu; Jochen Kruecker; Baris Turkbey; Neil Glossop; Anurag K Singh; Peter Choyke; Peter Pinto; Bradford J Wood Journal: Comput Aided Surg Date: 2008-09
Authors: Michael Kongnyuy; Daniel M Halpern; Corinne C Liu; Kaitlin E Kosinski; David J Habibian; Anthony T Corcoran; Aaron E Katz Journal: Int Urol Nephrol Date: 2017-08-10 Impact factor: 2.370
Authors: M Kongnyuy; M M Siddiqui; A K George; A Muthigi; A Sidana; M Maruf; B Turkbey; P L Choyke; B J Wood; P A Pinto Journal: Prostate Cancer Prostatic Dis Date: 2017-04-25 Impact factor: 5.554
Authors: Julie Y An; Abhinav Sidana; Sarah A Holzman; Joseph A Baiocco; Sherif Mehralivand; Peter L Choyke; Bradford J Wood; Baris Turkbey; Peter A Pinto Journal: Int Urol Nephrol Date: 2017-11-15 Impact factor: 2.370
Authors: Soroush Rais-Bahrami; Barış Türkbey; Ardeshir R Rastinehad; Annerleim Walton-Diaz; Anthony N Hoang; M Minhaj Siddiqui; Lambros Stamatakis; Hong Truong; Jeffrey W Nix; Srinivas Vourganti; Kinzya B Grant; Maria J Merino; Peter L Choyke; Peter A Pinto Journal: Diagn Interv Radiol Date: 2014 Jul-Aug Impact factor: 2.630
Authors: M Minhaj Siddiqui; Arvin K George; Rachel Rubin; Soroush Rais-Bahrami; Howard L Parnes; Maria J Merino; Richard M Simon; Baris Turkbey; Peter L Choyke; Bradford J Wood; Peter A Pinto Journal: J Natl Cancer Inst Date: 2016-04-29 Impact factor: 13.506